Abstract 1309
Background
Organized cervical cancer screening program for women aged 30 or over using Pap Smear has been launched in Korea since 1999. However, there is limited evidence showing the effectiveness of this nationwide screening program in reducing cervical cancer mortality. In this study, we aim to examine cervical cancer mortality among screened and non-screened women who participated in the Korean National Cancer Screening Program (KNCSP) from 2002 to 2003.
Methods
We conducted a prospective cohort study of women aged 30-79 years invited to the KNCSP between 2002 - 2003 and followed up to 2015 for deaths from cervical cancer and other causes. Women with incomplete ID, diagnosed with cervical cancer before entering the cohort, or older than 79 years were excluded. Finally, a total of 8,262,267 women aged 30-79 were included, and their cervical cancer screening exposure, cancer incidence, and death information were collected from the KNCSP database, National Cancer Registry, and death certificate from Statistics Korea. There were 6,615,614 women in the screen group (mean person-year: 9.74) and 5,814,989 women in the non-screen group (mean person-year: 8.33). Incidence rate ratio (IRR) and Mortality rate ratio (MRR) were used to compare between screen and non-screen cohorts using Poisson regression model. The MRRs and IRRs were adjusted for age at inclusion in the cohort, insurance type, and self-selection bias.
Results
The crude mortality rate was 3.49 and 8.77 per 100,000 women-years for screen and non-screen group, respectively. MRR for cervical cancer was 0.46 (95% confidence interval (CI): 0.44-0.48). After adjusting for self-selection bias, it was estimated that there was 36.11% of mortality reduction in screen group compared to non-screen group. Also, IRR of invasive cancer in screen group was 0.74 (95% CI: 0.72-0.76) compared to non-screen group. However, there was no significant reduction in the total number of invasive cervical cancer and cervical cancer in situ incidence rate (IRR: 0.98; 95%CI: 0.98 (0.96-1.00)).
Conclusions
We found that after 13 years of follow-up, 36.11% of cervical cancer mortality reduction was observed among women who attended the Korean National Cervical Cancer Screening Program.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kui Son Choi.
Funding
National Cancer Center, Korea (Grant number: 1610401) and International Cooperation & Education Program (NCCRI·NCCI 52210-52211,2019) of National Cancer Center, Korea.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1694 - Pembrolizumab (pembro) Plus mFOLFOX or FOLFIRI in Patients With Metastatic Colorectal Cancer (mCRC): KEYNOTE-651 Cohorts B and D
Presenter: Richard Kim
Session: Poster Display session 2
Resources:
Abstract
908 - Romidepsin (FK228) Regulates the Expression of the Immune Checkpoint Ligand PD-L1 and Exerts Synergistic Anti-Tumor Activity with an Anti-PD-1 Antibody in Colon Cancer
Presenter: Hui Li
Session: Poster Display session 2
Resources:
Abstract
3127 - Prognostic significance of circulating regulatory T lymphocytes (Tregs) in patients with metastatic colorectal cancer (mCRC) under treatment with first line chemotherapy.
Presenter: Zafeiris Zafeiriou
Session: Poster Display session 2
Resources:
Abstract
5416 - The SAFFO study: Sex-related prognostic role And cut-oFf deFinition of monocyte-to-lymphocyte ratio (MLR) in metastatic colOrectal cancer
Presenter: Camilla Lisanti
Session: Poster Display session 2
Resources:
Abstract
2518 - SPICE, a phase I study of enadenotucirev in combination with nivolumab in tumors of epithelial origin: analysis of the metastatic colorectal cancer patients in the dose escalation phase
Presenter: Marwan Fakih
Session: Poster Display session 2
Resources:
Abstract
4000 - Phase 1/2 study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer
Presenter: Niels Halama
Session: Poster Display session 2
Resources:
Abstract
2223 - Microsatellite Instability Status in Metastatic Colorectal Cancer and Effect of Immune Checkpoint Inhibitors on Survival in MSI-High Metastatic Colorectal Cancer
Presenter: Wataru Okamoto
Session: Poster Display session 2
Resources:
Abstract
2569 - Phase II trial of Trametinib (T) and Panitumumab (Pmab) in RAS/RAF wild type (wt) metastatic colorectal cancer (mCRC)
Presenter: Kanan Alshammari
Session: Poster Display session 2
Resources:
Abstract
5402 - Microsatellite instability and immunogenicity in colorectal cancer – do resident memory Tcells (Trm) play a role in colorectal cancer
Presenter: Wei Toh
Session: Poster Display session 2
Resources:
Abstract
5472 - Early response evaluation and CEA response in patients treated in a Danish randomized study comparing trifluridine/tipiracil (TAS-102) with or without bevazicumab in patients with chemorefractory metastatic colorectal cancer (mCRC)
Presenter: Camilla Qvortrup
Session: Poster Display session 2
Resources:
Abstract